04:28pm Tuesday 26 September 2017

Stem Cell Time Bombs Cause Leukaemia Relapse

Senior author Professor Mel Greaves from The Institute of Cancer Research (ICR) cautioned that the findings should not unduly concern parents whose children have previously suffered acute lymphoblastic leukaemia (ALL) as the leukaemia returning after very many years of remission is rare.  Also, the late relapse is usually genetically similar to the original cancer and the same treatment is likely to put them into remission once again.

“Some types of treatment eradicate the leukaemic cells, but do not kill all the leukaemic stem cells. Years later, if the patient is unlucky enough to be exposed to another trigger, the cancer can start developing again,” Professor Greaves says. “The good news is that we believe some new schedules of treatment for leukaemia may also kill the stem cells, so in future patients may not have this risk of relapse.”

In 2008, Professor Greaves and his team at the ICR confirmed the existence of the leukaemia stem cell, which develops from a genetic mutation when the patient is still in the womb.

The mutation – the fusion of the TEL (ETV6) and AML1 (RUNX1) genes – generates pre-leukaemic cells that grow in the bone marrow as a silent time bomb, but require other factors to convert them into leukaemia. Evidence suggests that the mutation may be present in as many as one in 100 newborns, but only about one in 100 of those children with the mutation then go on to develop ALL. These triggers are thought to include acquiring a common childhood infection and further genetic mutations.

In the latest study, supported by Leukaemia & Lymphoma Research and The Kay Kendall Leukaemia Fund and published in the current edition of the journal Blood, the scientists scanned the DNA of cancer samples taken from 21 patients at first diagnosis and then at relapse. All the patients had the ETV6-RUNX1 fusion and were aged on average 4.5 years at diagnosis, with first relapse up to ten years later.

For each patient, they found an average of around eight different mutations, known as copy number alternations, at diagnosis and around 11 at relapse. Some of these were thought to be unimportant “passenger” mutations, but a number of “driver” mutations – thought to be directly involved in cancer development – were identified due to their frequency among the patients or previously known role in ALL development. By analysing driver mutations present at both stages, they confirmed the cancer cells causing relapse were derived from cells present at first diagnosis, in most cases at low levels.

For one patient, they performed backtracking analysis using a technique called fluorescence in situ hybridization (FISH) and identified a cancer cell present at low levels at diagnosis (0.4%) whose genotype actually matched the dominant cancer cells (79.8%) observed at relapse ten years later.

The study findings also raise the possibility that patients at risk of the cancer returning could be identified by using sensitive molecular screening methods to look for persisting stem cells.

“It may be possible to examine patients once they have finished treatment – usually two to three years after diagnosis – and determine if they still have a reservoir of leukaemic stem cells and therefore potential for relapse,” lead author Frederik van Delft from the ICR says.

 -ENDS-

Media Contact: ICR Science Communications Manager Jane Bunce on 0207 153 5106 or after hours 077217 47900

 

Notes to Editors:

 

Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia by Frederik van Delft et al. published in Blood Volume 117, number 23 on June 9 2011.

 

The study was a collaboration between scientists at the ICR, Great Ormond Street Hospital, Charles University in Prague, Charité – Medical University in Berlin and University of Manchester and Central Manchester Hospitals University Trust. The ICR team includes Frederik W. van Delft, Sharon Horsley, Sue Colman, Kristina Anderson, Caroline Bateman, Lyndal Kearney, Anthony Ford and Mel Greaves.

 

The Institute of Cancer Research (ICR)

  • The ICR is Europe’s leading cancer research centre
  • The ICR has been ranked the UK’s top academic research centre, based on the results of the Higher Education Funding Council’s Research Assessment Exercise
  • The ICR works closely with partner The Royal Marsden NHS Foundation Trust to ensure patients immediately benefit from new research. Together the two organisations form the largest comprehensive cancer centre in Europe
  • The ICR has charitable status and relies on voluntary income, spending 90 pence in every pound of total income directly on research
  • As a college of the University of London, the ICR also provides postgraduate higher education of international distinction
  • Over its 100-year history, the ICR’s achievements include identifying the potential link between smoking and lung cancer which was subsequently confirmed, discovering that DNA damage is the basic cause of cancer and isolating more cancer-related genes than any other organisation in the world

For more information visit www.icr.ac.uk

Leukaemia & Lymphoma Research

Leukaemia & Lymphoma Research is the only UK charity solely dedicated to research into blood cancers, including leukaemia, lymphoma and myeloma. These cancers are diagnosed in around 28,500 children, teenagers and adults in the UK every year. As we receive no government funding and rely entirely on voluntary support, we need to raise £120 million in the next five years to continue our life-saving research. Further information, including patient information booklets, is available from www.beatbloodcancers.org or on 020 7405 0101.

The Kay Kendall Leukaemia Fund

The Kay Kendall Leukaemia Fund awards grants for research on aspects of leukaemia and for relevant studies on related haematological malignancies. Grants are awarded for first class research on innovative proposals, particularly those close to the care of leukaemia patients or the prevention of leukaemia or related diseases. Project grants are awarded twice yearly, and Senior, Intermediate and Junior Fellowships of three to five years are awarded annually. The Fund also considers support for capital projects that will have direct benefit to leukaemia patient care.  For more information please visit www.kklf.org.uk.


Share on:
or:

Health news